ArticleGastro hep advances2026
Anatomical Distribution and Prevalence of Dysplasia in Sessile Serrated Lesions: A Cohort Study Over Seven Years.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Sessile serrated lesions (SSLs) progress to colorectal cancer via a critical intermediary stage, SSL with dysplasia (SSLd). Data on the anatomical distribution of SSLd are limited, particularly in high-detection-rate settings. This study aimed to assess the prevalence and anatomical distribution of dysplasia in SSLs from a single-endoscopist practice with a consistently high SSL detection rate over 7 years. Methods: A retrospective analysis was conducted on all SSLs submitted to private pathology from a single endoscopist at Port Macquarie, Australia, between January 2019 and December 2025. Pathology reports were systematically reviewed, and terminology was standardized according to the 2019 World Health Organization Classification of Tumours of the Digestive System. Dysplasia was classified as a binary variable (present or absent) and attributed specifically to the SSL component. All specimens initially identified as SSLd were presented at the institutional histopathology meeting for review and reclassified where appropriate. Results: A total of 3570 SSLs were identified across 2701 colonoscopy episodes. On initial pathology reporting, 102 SSLs were identified as harboring dysplasia (2.86%). After histopathology meeting review, 9 were reclassified (collision-type lesions of separate tubular adenoma and SSL in 3 cases, no dysplasia on review in 3 cases, traditional serrated adenoma in 2 cases, and conventional adenoma with a serrated growth pattern in 1 case), leaving 93 confirmed SSLd (2.61%). The confirmed dysplasia rate did not differ significantly between proximal (52/2114; 2.46%) and distal (25/824; 3.03%) colonic locations ( Conclusion: In a large single-endoscopist pathology cohort, 2.61% of SSLs harbored confirmed cytological dysplasia after histopathology review. The reclassification rate of 8.8% was lower than the 33.3% reported in a prospective study with formal dual-expert pathologist review, though the pattern of reclassification was similar. Dysplasia was distributed throughout the colorectum without a significant proximal-distal predilection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.